Core Viewpoint - The company announced the cancellation of 180,000 unvested restricted stocks from its 2022 A-share incentive plan due to the departure of five incentive recipients who no longer meet the eligibility criteria [8][9][40]. Group 1: Incentive Plan Approval and Implementation - The company held its first board meeting on October 16, 2022, to approve the draft of the 2022 A-share restricted stock incentive plan and its implementation management measures [22][31]. - The plan involves granting a total of 3.58 million restricted stocks, representing approximately 0.6578% of the company's total share capital at the time of the announcement [22][23]. - The initial grant includes 872,305 A-class stocks and 1,996,400 B-class stocks, with a grant price of 36.36 yuan per share [22][23]. Group 2: Cancellation of Restricted Stocks - The board of directors approved the cancellation of 180,000 restricted stocks that were granted but not vested due to the departure of five recipients [8][40]. - This cancellation will not significantly impact the company's operational status or the stability of its technical and management teams [9][40]. Group 3: Legal and Compliance Aspects - The company has fulfilled necessary approvals and disclosures in accordance with relevant laws and regulations regarding the cancellation of the restricted stocks [11][44]. - The legal opinion confirms that the cancellation and the overall incentive plan comply with the applicable laws and regulations [11][44].

Core Viewpoint - The independent financial advisor report by Shanghai Miaodao Enterprise Management Consulting Co., Ltd. confirms that the conditions for the third vesting period of the 2022 A-share restricted stock incentive plan of Kanglong Chemical (Beijing) New Drug Technology Co., Ltd. have been met, although the stocks will not be listed immediately [1][10]. Group 1: Approval Process - The board of directors and the supervisory board approved the incentive plan and its related matters in multiple meetings held in March and May 2022 [6][7]. - The company conducted a public announcement of the list of incentive objects, which received no objections during the public notice period [6][7]. - The board and supervisory board held meetings in July 2022 to approve adjustments to the grant price and quantity of the restricted stocks [7]. Group 2: Vesting Conditions - The third vesting period for the restricted stocks is defined as the first trading day after 36 months from the grant date until the last trading day within 48 months from the grant date, allowing for a vesting ratio of 25% of the total granted stocks [11]. - The company’s 2024 revenue must increase by at least 60% compared to the 2021 revenue, which was approximately 7.44 billion yuan, to meet the performance conditions [13]. - A total of 336 incentive objects met the personal performance evaluation criteria, with 100% of them qualifying for the vesting [15]. Group 3: Stock Listing and Trading Restrictions - The vesting date for the restricted stocks is set for July 28, 2025, but the stocks will remain under a trading restriction for six months post-vesting [18]. - The company will apply for the listing of the vested stocks after the trading restriction period ends on January 27, 2026 [18]. Group 4: Independent Financial Advisor's Opinion - The independent financial advisor confirms that all conditions for the vesting of the restricted stocks have been satisfied and that the necessary approvals have been obtained, ensuring compliance with relevant laws and regulations [19].